Publication date
August 2016
DOIAbstract
ijbms.mums.ac.ir Ultraviolet B efficacy in improving antileishmanial effects of silver nanoparticle
ijbms.mums.ac.ir Ultraviolet B efficacy in improving antileishmanial effects of silver nanoparticle
International audienceLeishmaniasis is a widely distributed protozoan vector-born disease affecting ...
Background & objectives: Cutaneous leishmaniasis is an infection caused by protozoan genus Leishmani...
Leishmaniasis is a serious public health problem throughout the developing world; 350 million people...
The drugs used to treat cutaneous leishmaniasis (CL) cannot effectively penetrate lesions. Nanogold ...
Adil M Allahverdiyev1, Emrah Sefik Abamor1, Malahat Bagirova1, Cem B Ustundag2, Cengiz Kaya2, Figen ...
In Leishmania the glutathione/glutathione reductase eukaryotic redox sys-tem is replaced by the uniq...
Leishmaniasis is an epidemic disease that affects the human body and is transmitted through the bite...
Leishmania parasites are the etiological agents of Leishmaniasis, a tropical disease that affects ar...
Objective: Leishmaniasis is endemic in 88 countries with incidence rate of 1.5-2 million; the most c...
Purpose In the treatment of cutaneous leishmaniasis (CL), developing drug resistance, existing toxic...
Silver nanoparticles have been studied as an alternative for treatment of microbial infections and ...
Background: Cutaneous leishmaniasis (CL) is a disease of public health importance in Nigeria, with h...
Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimonia...
Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (ML) show clinical spectra that can ran...
International audienceParenteral administration of amphotericin B-deoxycholate (AmB-DOC) or pentaval...
International audienceLeishmaniasis is a widely distributed protozoan vector-born disease affecting ...
Background & objectives: Cutaneous leishmaniasis is an infection caused by protozoan genus Leishmani...
Leishmaniasis is a serious public health problem throughout the developing world; 350 million people...
The drugs used to treat cutaneous leishmaniasis (CL) cannot effectively penetrate lesions. Nanogold ...
Adil M Allahverdiyev1, Emrah Sefik Abamor1, Malahat Bagirova1, Cem B Ustundag2, Cengiz Kaya2, Figen ...
In Leishmania the glutathione/glutathione reductase eukaryotic redox sys-tem is replaced by the uniq...
Leishmaniasis is an epidemic disease that affects the human body and is transmitted through the bite...
Leishmania parasites are the etiological agents of Leishmaniasis, a tropical disease that affects ar...
Objective: Leishmaniasis is endemic in 88 countries with incidence rate of 1.5-2 million; the most c...
Purpose In the treatment of cutaneous leishmaniasis (CL), developing drug resistance, existing toxic...
Silver nanoparticles have been studied as an alternative for treatment of microbial infections and ...
Background: Cutaneous leishmaniasis (CL) is a disease of public health importance in Nigeria, with h...
Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimonia...
Cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (ML) show clinical spectra that can ran...
International audienceParenteral administration of amphotericin B-deoxycholate (AmB-DOC) or pentaval...
International audienceLeishmaniasis is a widely distributed protozoan vector-born disease affecting ...
Background & objectives: Cutaneous leishmaniasis is an infection caused by protozoan genus Leishmani...
Leishmaniasis is a serious public health problem throughout the developing world; 350 million people...
Add to ORKG